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Abstract: Biotin molecules could be used as suitable targeting moieties in targeted drug delivery 
systems against tumors. To develop a biotin targeted drug delivery system, we employed human 
serum albumin (HSA) as a carrier. Methotrexate (MTX) molecules were conjugated to HSA. 
MTX-HSA nanoparticles (MTX-HSA NPs) were prepared from these conjugates by cross-linking 
the HSA molecules. Biotin molecules were then conjugated on the surface of MTX-HSA NPs. 
The anticancer efficacy of biotin targeted MTX-HSA NPs was evaluated in mice bearing 4T1 
breast carcinoma. A single dose of biotin targeted MTX-HSA NPs showed stronger in vivo 
antitumor activity than non-targeted MTX-HSA NPs and free MTX. By 7 days after treatment, 
average tumor volume in the biotin targeted MTX-HSA NPs-treated group decreased to 17.6% of 
the initial tumor volume when the number of attached biotin molecules on MTX-HSA-NPs was 
the highest. Average tumor volume in non-targeted MTX-HSA NPs-treated mice grew rapidly 
and reached 250.7% of the initial tumor volume. Biotin targeted MTX-HSA NPs increased the 
survival of tumor-bearing mice to 47.5 ± 0.71 days and increased their life span up to 216.7%. 
Mice treated with biotin targeted MTX-HSA NPs showed slight body weight loss (8%) 21 days 
after treatment, whereas non-targeted MTX-HSA NPs treatment at the same dose caused a body 
weight loss of 27.05% ± 3.1%.
Keywords: biotin, targeted drug delivery, in vivo anticancer delivery, human serum albumin, 
methotrexate, conjugates
Introduction
The side effects of anticancer drugs could limit the efficacy of cancer chemotherapy.1–2 
Targeted drug delivery systems could diminish the adverse cytotoxic effects of antican-
cer drugs on normal tissues.3 Specific drug delivery to cancers could be achieved by 
adding a suitable targeting moiety on drug delivery systems.4 These targeting moieties 
could bind to certain types of receptors on the tumor cells and deliver cytotoxic drug 
to these cells specifically. Several targeting agents such as antibodies,5,6 peptides,7,8 
vitamins,9 folic acid,10–14 and integrin15 could be used as suitable targeting moieties in 
targeted drug delivery systems. Among vitamins, biotin (vitamin H) has been used as 
a suitable targeting agent in several studies.16–18 Biotin receptors overexpressed on the 
surface of different cancer cells could internalize sufficiently the biotin targeted drug 
delivery system into these cells.18
In this study biotin was used as a targeting moiety to design a tumor targeted drug 
delivery system based on a human serum albumin (HSA) conjugation strategy. The 
biotin targeted drug delivery system consisted of (i) HSA as carrier; (ii) methotrexate 
(MTX) as anticancer drug; and (iii) biotin as a targeting moiety. MTX was conjugated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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to HSA and then MTX-HSA nanoparticles (MTX-HSA NPs) 
were prepared by cross-linking the HSA molecules using 
EDC cross-linker. The surface of MTX-HSA NPs was then 
functionalized by biotin molecules using a carbodiimide reac-
tion. The targeting effect of biotin targeted MTX-HSA NPs 
to tumor cells were confirmed successfully in vitro.19
4T1 breast carcinoma derived from the Balb/c mammary 
carcinoma is a transplantable tumor cell line that is a highly 
malignant and invasive tumor model and can metastasize 
from the primary tumor in the mammary gland to other sites 
including lymph nodes, blood, liver, lung, brain, and bone.20 
The 4T1 tumor resembles advanced breast cancer in humans 
and can be used as a suitable experimental model for human 
mammary cancer.21 The 4T1 model can be used for deter-
mination of the effects of anticancer drugs such as MTX on 
breast tumor growth and metastasis efficiently. Moreover the 
4T1 model can be used as a model for evaluation of biotin 
targeted drug delivery systems because of the overexpression 
of biotin receptors on the surface of these tumor cells.22 The 
aim of this study was to evaluate the antitumor effect of biotin 
targeted MTX-HSA NPs compared with non-targeted MTX-
HSA NPs on mice bearing 4T1 tumor in vivo. The effects 
of biotin targeted MTX-HSA NPs on the survival and body 
weight loss of 4T1 tumor-bearing mice were also evaluated.
Materials and methods
Materials
Methotrexate USP was kindly donated by Cipla Pharmaceuti-
cal Co, India. Biotin was obtained from Sigma-Aldrich (St 
Louis, MO). 1-ethyl-3-(diaminopropyl) carbodiimde HCl 
(EDC), N-hydroxysuccinimide (NHS) and human serum 
albumin, HABA/Avidin and ﬂuorescein isothiocyanate (FITC) 
were purchased from Sigma-Aldrich (Steinheim, Germany). 
RPMI-1640 modified medium and penicillin–streptomycin 
solution were obtained from Gibco Invitrogen (Calsbad, CA). 
Deionized water was used throughout the experiment. All 
other chemicals used were of reagent grade.
Preparation of biotin functionalized 
MTX-hsA NPs
MTX was conjugated to HSA by a carbodiimide reaction 
using EDC and NHS.23 Then MTX-HSA conjugates were 
cross-linked using EDC to form MTX-HSA NPs. For deter-
mination of MTX/HSA molar ratio in MTX-HSA NPs, free 
MTX was dissolved in 0.1 N NaOH. The absorbance of MTX 
solution was determined using UV   spectrophotometry in 
372 nm. The calibration plot of MTX solution was   linear in 
the range of 0.005–0.2 mg/mL. It could be assumed that the 
molar absorptivity of MTX was not changed by conjugation 
to HSA.24 Thus, 12.5 mg of MTX-HSA NPs was accurately 
weighed and redispersed in 4 mL of 0.1 N NaOH. MTX 
content was determined using UV absorbance of the MTX-
HSA NPs solution at 372 nm. Moreover, HSA absorbance 
was negligible at this wavelength. HSA content of NPs was 
determined using a Total Protein Kit, Micro Lowry, Peterson’s 
Modification (Sigma-Aldrich). In this study, we used MTX-
HSA NPs with an MTX/HSA molarity ratio of 8 ± 0.18. 
For conjugation of biotin on the surface of MTX-HSA NPs, 
50 mg of biotin, 25 mg of NHS, and 40 mg of EDC were 
dissolved in dimethyl sulfoxide (DMSO) (5 mL). The DMSO 
solution was placed at room temperature for 1 hour. Thirty 
milligrams of MTX-HSA NPs (MTX/HSA molar ratio = 8) 
were resuspended in 1 mL sodium bicarbonate solution 
(0.1 M). The MTX-HSA NPs solution was divided into three 
equal parts. Different amounts of the DMSO solution (600, 
1000, and 1500 µL) were added to MTX-HSA NPs solutions. 
The obtained mixtures of MTX-HSA NPs and DMSO solu-
tion were stirred constantly at room temperature for 16 hours. 
After an appropriate time the mixture was dialyzed against 
phosphate-buffered saline (PBS) (pH 7.2) using cellulose 
membrane (cutoff 12 kDa; Merck, Germany) overnight for 
removing unreacted biotin, N-hydroxysuccinimide, EDC, 
and DMSO. The biotin functionalized MTX-HSA NPs were 
lyophilized at −40°C for 48 hours using a Lyotrap Plus lyo-
philizator (LTE, Scientific Ltd, Oldham, UK). The amount 
of biotin attached on the surface of MTX-HSA NPs was 
determined using HABA/Avidin complex. Biotin functional-
ized MTX-HSA NPs (1 mg) were resuspended in 1 mL of 
deionized water. HABA/Avidin solution (900 µL, 20 mg in 
1 mL deionized water) was added to 100 µL of the solution 
containing biotin functionalized MTX-HSA NPs. Biotin con-
tent of the NPs was determined using UV spectrophotometry 
at 500 nm wavelength.25 The amount of biotin molecules was 
determined using the following formula:
∆ A500 = 0.9 × (HABA/Avidin absorbance) 
   – (HABA/Avidin and biotin functionalized
  MTX-HSA NPs absorbance)
  Biotin concentration (µM) = (∆ A500/34) × 10
Three types of biotin functionalized MTX-HSA NPs 
with 3.66 ± 0.22, 7.01 ± 0.14 and 9.41 ± 0.34 biotin/HSA 
molar ratios were prepared. Biotin functionalized MTX-HSA 
NPs with 3.66 ± 0.22, 7.01 ± 0.14 and 9.41 ± 0.34 biotin/
HSA molar ratios were named biotin 3.66-MTX-HSA NPs, 
  biotin 7.01-MTX-HSA NPs and biotin 9.41-MTX-HSA 
NPs, respectively.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Particle size and zeta potential  
measurement of biotin functionalized  
MTX-hsA NPs
One milligram of the lyophilized biotin functionalized MTX-
HSA NPs was resuspended in 1 mL deionized water. Particle 
sizes, polydispersity, and zeta potential of the biotin func-
tionalized MTX-HSA NPs were determined using Zetasizer 
ZS (Malvern Instruments, Malvern, UK).
Further characterization of NPs (eg, transmission electron 
microscopy images, ﬂuorescence microscopy images of cel-
lular uptake of NPs) and their in vitro drug release profile 
are given as supplementary data.
cell line
Breast tumor 4T1 cell line was purchased from the American 
Type Culture Collection (Manassas, VA) and cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum and 
1% penicillin–streptomycin.
Animal tumor model
The ability of biotin-functionalized NPs to target MTX to 
tumors was evaluated in the 4T1 tumor model. The effect of 
single-dose biotin targeted MTX-HSA NPs, non-targeted 
MTX-HSA NPs, and free MTX treatment on tumor growth 
was investigated in mice bearing 4T1 tumor, which are 
known to overexpress biotin receptors.22 All in vivo experi-
ments were conducted according to the guidelines of ethical 
committee of the Pharmaceutical Research Centre, Faculty 
of Pharmacy, Tehran University of Medical Sciences, Iran. 
The female Balb/c mice of body weight 17–20 g were pur-
chased from the Pasteur Institute (Tehran, Iran). 4T1 breast 
tumor cells (106–107) were inoculated subcutaneously into 
the breast region of each female Balb/c mouse (6–8 weeks 
old) in a volume of 0.2 mL. Animals had free access to food 
and water. When the tumor sizes of 95% of tumor-bearing 
mice were . 200 ± 105 mm3, the mice were divided into 
11 groups. There were 22 mice in the group treated with 
normal saline and seven mice in each of the other groups; 
five to six mice that had approximately the same tumor 
size were placed in one group. Two different doses of 
biotin targeted MTX-HSA NPs, non-targeted MTX-HSA 
NPs, and free MTX were injected to mice intravenously 
via the tail vein. The doses were equivalent to 6.25 and 
12.5 mg/kg of free MTX. Normal saline was injected in 
to all animals of the control group. On day 0 before treat-
ment, the mean tumor volumes of animals in groups treated 
with normal saline, free MTX (6.25 mg/kg), free MTX 
(12.5 mg/kg), MTX-HSA NPs   (equivalent MTX 6.25 mg/kg), 
MTX-HSA NPs (equivalent MTX 12.5 mg/kg), biotin 
3.66-MTX-HSA NPs (equivalent MTX 6.25 mg/kg), biotin 
3.66-MTX-HSA NPs (equivalent MTX 12.5 mg/kg), bio-
tin 7.01-MTX-HSA NPs (equivalent MTX 6.25 mg/kg), 
biotin 7.01-MTX-HSA NPs (equivalent MTX 12.5 mg/kg), 
biotin 9.41-MTX-HSA NPs (equivalent MTX 6.25 mg/
kg), and biotin 9.41-MTX-HSA NPs (equivalent MTX 
12.5 mg/kg) were 242.91 ± 181.17, 281.22 ± 158.34, 
318.52 ± 141.44, 202.37 ± 376, 237.23 ± 111.71, 
262.02 ± 146.70, 304.04 ± 101.34, 348.01 ± 98.56, 
255.67 ± 88.45, 313.29 ± 111.23, 258.78 ± 67.45, respec-
tively. The size of tumors at day 0 was taken as 100%. Tumor 
sizes of each group were determined until 3 weeks after 
treatment with free MTX, biotin targeted MTX-HSA NPs, 
and non-targeted MTX-HSA NPs. The volume of tumors 
was measured using digital caliber and calculated using the 
following formula:
  0.4 (L · W2)
L was the length and W was the width of the tumors.26
Determination of median survival time  
and percentage increase in life span
Animal survival time was monitored by recording the median 
survival time (MST) in days and percentage increase in life 
span (ILS%) of mice treated with biotin targeted MTX-HSA 
NPs, non-targeted MTX-HSA NPs, and free MTX. Median 
survival time and percentage increase in lifespan (ILS%) 
was calculated using the following formula:27
Median survival time (MST) =   (day of 1st death  
+ day of last death)/2
Percentage increase  
  in life span =   [(MST of treated group 
/MST of control group) – 1] × 100
evaluation of body weight loss
The antitumor efficacy of biotin targeted MTX-HSA NPs 
could be evaluated by inhibitory effects of these NPs on the 
weight loss of tumor-bearing mice.28 Consequently the body 
weight of 4T1 tumor-bearing mice treated with free MTX, 
non-targeted and biotin targeted MTX-HSA NPs was also 
recorded every 3 days during the study. The doses were 
equivalent to 6.25 mg/kg of free MTX.
Data analysis
Data were analyzed by one-way analysis of variance (ANOVA). 
P , 0.05 was considered statistically significant.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results
characterization of biotin functionalized  
MTX-hsA NPs
The conjugation of biotin on the surface of MTX-HSA NPs 
(MTX/HSA molar ratio: 8) increased the size of these NPs 
from 111.7 ± 4.6 to 125–145 nm according to the amount of 
attached biotin molecules. The biotin functionalization of MTX-
HSA NPs increased the negative surface charge of these NPs 
from –12.1 ± 0.5 mV to –20.45 ± 0.2 mV . Particle size, zeta 
potential, and biotin content for biotin functionalized and non-
functionalized MTX-HSA NPs are summarized in Table 1. Fur-
ther information regarding preparation and characterization of 
fractionalized MTX-HSA NPs are reported as supplements.
In vivo anticancer efficacy of biotin  
targeted NPs
As can be seen in Figure 1 tumor volumes in saline-treated 
mice increased rapidly (Figure 1). At the doses used (equiva-
lent to 6.25 and 12.5 mg/kg free MTX), free MTX did not 
have a significant inhibitory effect on tumor growth compared 
with the control group (saline group). The inhibitory tumor 
growth effect of non-targeted MTX-HSA NPs was only 1.54- 
to 1.98-fold more than free MTX at similar concentration. 
Conjugation of biotin molecules on the surface of MTX-
HSA NPs significantly enhanced inhibitory tumor growth 
effects of MTX-HSA NPs on the 4T1 tumor model. Biotin 
7.01-MTX-HSA NPs at doses of 6.25 and 12.5 mg/kg of 
equivalent free MTX significantly (P , 0.05) reduced tumor 
volume in a dose-dependent manner compared with non-
targeted NPs. A significant antitumor effect in mice treated 
with biotin targeted NPs was observed after 4 days and up to 
21 days (P , 0.05) of treatment. At the end of the study of 
antitumor effect (day 21), mean tumor volume in the groups 
treated with biotin 9.41-MTX-HSA NPs, biotin 7.02-MTX-
HSA NPs, and biotin 3.66-MTX-HSA NPs was 8.46 ± 2.3-, 
4.88 ± 1.23-, and 3.74 ± 1.05-fold lower than that in the 
group treated with non-targeted MTX-HSA NPs (at doses 
equivalent to 12.5 mg/kg of free MTX) (Figure 2). By 7 days 
after injection, average tumor volume in groups treated with 
biotin 9.41-MTX-HSA NPs, biotin 7.02-MTX-HSA NPs, 
and biotin 3.66-MTX-HSA NPs (12.5 mg/kg of equivalent 
free MTX) was only 17.67% ± 7.78%, 28.56% ± 8.46%, 
and 34.44% ± 8.22% of the initial tumor volume, whereas 
the average tumor volume in mice treated with non-targeted 
MTX-HSA NPs (equivalent to 12.5 mg/kg free MTX) grew 
rapidly and reached 250.78% ± 29.01% of the initial tumor 
volume. Increasing the amount of attached biotin molecules 
on the surface of MTX-HSA NPs increased the antitumor 
effect of biotin targeted NPs (Figure 2).
Biotin targeted NPs prolonged survival  
of tumor-bearing mice
The effect of biotin targeted NPs on the survival of 4T1 
tumor-bearing mice is shown in Figure 3 and Table 2. Biotin 
targeting increased the median survival time of 4T1 tumor-
bearing mice significantly compared with non-targeted 
MTX-HSA NPs. MST of the control group that received only 
saline was 15.01 ± 0.79 days, whereas it was 17.51 ± 0.60, 
22.52 ± 0.5, 32.5 ± 0.41, 37.5 ± 0.67, and 47.5 ± 0.71 days 
for groups treated with free MTX, non-targeted MTX-HSA 
NPs, biotin 3.66-MTX-HSA NPs, biotin 7.02-MTX-HSA,   
NPs, and biotin 9.41-MTX-HSA NPs, respectively (equivalent 
to 6.25 mg/kg free MTX). The increase in the life span of 4T1 
tumor-bearing mice treated with free MTX and non-targeted 
MTX-HSA NPs was 16.66% and 50.10%, respectively. The 
increase in the life span of mice treated with biotin 3.66-MTX-
HSA NPs, biotin 7.02-MTX-HSA NPs, and biotin 9.41-MTX-
HSA NPs was 116.66%, 150.1%, and 216.66%, respectively.
evaluation of body weight loss
There were no significant differences in weight change 
among the groups treated with biotin 3.66-MTX-HSA NPs, 
Table 1 Physico-chemical characteristics of MTX-hsA NPs (MTX/hsA molar ratio = 8) and biotin functionalized MTX-hsA NPs 
(mean ± standard deviation; n = 3)
Biotin/HSA molar ratio MTX-HSA  
NPs
Biotin 3.66-MTX-HSA  
NPs
Biotin 7.01-MTX-HSA  
NPs
Biotin 9.41-MTX-HSA   
NPs
0 3.66 ± 0.22 7.01 ± 0.14 9.41 ± 0.34
Particle size (nm) 111.70 ± 4.60 125.10 ±3 .40 132.40 ± 2.14 144.36 ± 3.80
Poly dispersity index   0.10 ± 0.01   0.21 ± 0.07   0.19 ± 0.04   0.24 ± 0.05
Zeta potential (mV) –12.10 ± 0.5 –20.23 ± 1.11 –19.56 ± 2.01 –21.54 ± 1.25
Abbreviations: MTX-hsA NPs, methotrexate–human serum albumin conjugated nanoparticles; biotin 3.66-MTX-hsA NPs, biotin targeted methotrexate–human serum 
albumin nanoparticles: 3.66 ± 0.22 biotin/human serum albumin molar ratio; biotin 7.01-MTX-hsA NPs, biotin targeted methotrexate-human serum albumin nanoparticles: 
7.01 ± 0.14 biotin/human serum albumin molar ratio; biotin 9.41-MTX-hsA NPs, biotin targeted methotrexate–human serum albumin nanoparticles: 9.41 ± 0.34 biotin/
human serum albumin molar ratio.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Antitumor effect of free MTX, MTX-hsA NPs, and biotin 7.01-MTX-hsA NPs on 4T1 tumor-bearing mice. 4T1 tumor cells were implanted subcutaneously in 
Balb/c mice. The drugs were injected intravenously in a single dose (day 0). The doses were equivalent to 6.25 and 12.5 mg/kg of free MTX. Data are presented as mean ± 
standard deviation of relative tumor volumes (day 0 taken as 100%).
Abbreviations:  MTX,  methotrexate;  MTX-hsA  NP,  methotrexate–human  serum  albumin  conjugated  nanoparticle;  biotin  7.01-MTX-hsA  NPs,  biotin  targeted 
methotrexate–human serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratio.
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Figure 2 Antitumor effect of MTX-hsA NPs, biotin 3.66-MTX-hsA NPs, biotin 7.01-MTX-hsA NPs, and biotin 9.41-MTX-hsA NPs on 4T1 tumor-bearing mice. 4T1 tumor 
cells were implanted subcutaneously in Balb/c mice. The drugs were injected intravenously in a single dose (day 0). The doses were equivalent to 12.5 mg/kg of free MTX. 
Data are presented as mean ± standard deviation of relative tumor volumes (day 0 taken as 100%).
Abbreviations:  MTX,  methotrexate;  MTX-hsA  NP,  methotrexate–human  serum  albumin  conjugated  nanoparticle;  biotin  3.66-MTX-hsA  NPs,  biotin  targeted 
methotrexate–human serum albumin nanoparticles: 3.66 ± 0.22 biotin/human serum albumin molar ratio; biotin 7.01-MTX-hsA NPs, biotin targeted methotrexate–human 
serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratio; biotin 9.41-MTX-hsA NPs, biotin targeted methotrexate–human serum albumin 
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Figure 3 Animal survival study. The 4T1 tumor-bearing mice were treated with free MTX, MTX-hsA NPs, biotin 3.66-MTX-hsA NPs, biotin 7.02-MTX-hsA NPs, and biotin 
9.41-MTX-hsA NPs. The drugs were injected intravenously in a single dose (day 0). The doses were equivalent to 12.5 mg/kg of free MTX. The curve shows the number of 
4T1 tumor-bearing mice still alive on different days.
Abbreviations:  MTX,  methotrexate;  MTX-hsA  NP,  methotrexate–human  serum  albumin  conjugated  nanoparticle;  biotin  3.66-MTX-hsA  NPs,  biotin  targeted 
methotrexate–human serum albumin nanoparticles: 3.66 ± 0.22 biotin/human serum albumin molar ratio; biotin 7.02-MTX-hsA NPs, biotin targeted methotrexate–human 
serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratios; biotin 9.41-MTX-hsA NPs, biotin targeted methotrexate–human serum albumin 
nanoparticles: 9.41 ± 0.34 biotin/human serum albumin molar ratio.
Table 2 effect of biotin targeting on the survival of 4T1 tumor-
bearing mice
Group Median survival  
time (day)
Life span 
increase (%)
saline 15.01 ± 0.79 –
MTX 17.51 ± 0.60 16.66
MTX-hsA NPs 22.52 ± 0.50 50.10
Biotin 3.66-MTX-hsA NPs   32.5 ± 0.41 116.66
Biotin 7.01-MTX-hsA NPs   37.5 ± 0.67 150.10
Biotin 9.41-MTX-hsA NPs   47.5 ± 0.71 216.66
Note: *The dose was equivalent to 6.25 mg/kg of free MTX.
Abbreviations:  MTX,  methotrexate;  MTX-hsA  NPs,  methotrexate–human 
serum albumin conjugated nanoparticles; biotin 3.66-MTX-hsA NPs, biotin targeted 
methotrexate–human serum albumin nanoparticles: 3.66 ± 0.22 biotin/human serum 
albumin molar ratios; biotin 7.02-MTX-hsA NPs, biotin targeted methotrexate–
human serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar 
ratio;  biotin  9.41-MTX-hsA  NPs,  biotin  targeted  methotrexate–human  serum 
albumin nanoparticles: 9.41 ± 0.34 biotin/human serum albumin molar ratio.
biotin 7.02-MTX-HSA NPs, and biotin 9.41-MTX-HSA NPs 
(Figure 4), nor were there significant differences between 
groups treated with free MTX and non-targeted MTX-HSA 
NPs and the group that received only saline. But the weight 
change of the groups treated with biotin targeted MTX-HSA 
NPs differed significantly from that of the group treated with 
non-targeted MTX-HSA NPs, especially between days 9 
and 21. A body weight loss of ,8% of initial body weight 
would be almost tolerable.28 The body weight loss of tumor-
bearing mice treated with biotin targeted MTX-HSA NPs 
was ,8% of initial body weight, but mice treated with free 
MTX and non-targeted MTX-HSA NPs lost 21.9% ± 5.1% 
and 18.7% ± 6.4% of their body weight, respectively, after 
12 days.
Discussion
The use of HSA NPs in targeted drug delivery systems has 
been well reported.29,30 HSA represents a biodegradable drug 
carrier system with the capacity to deliver a large payload 
of cytotoxic drug to the tumor site.31,32 The free amino and 
carboxylic acid groups of HSA could be used for covalent 
coupling of cytotoxic drugs and targeting moieties.31,33–35 
Therefore HSA NPs have been proposed as a suitable drug 
carrier system for targeted drug delivery to specific tumor 
sites.36 Conjugation of cytotoxic drugs to HSA could improve 
their antitumor efficacy and decrease their toxic side effects.32 
Because of the overexpression of biotin receptors on the sur-
face of many tumor cells, biotin molecules could be used as 
a suitable targeting moiety in targeted drug delivery systems. 
Exploring this approach, Patil et al17 recently have reported 
the specific targeting of MCF-7 and 4T1 tumor cells with 
biotin molecules coupled on the PEG-PLA NPs containing 
paclitaxel and tariquidar (a P-gp modulator). They showed International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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that the uptake of biotin functionalized PEG-PLA NPs by 
tumor cells in vitro was specific. Moreover, biotin targeted 
paclitaxel loaded NPs had much higher antitumor effects 
than non-targeted NPs in vivo.
In our previous study, we first developed MTX-HSA con-
jugates, and then MTX-HSA conjugated NPs by cross-linking 
of HSA molecules using EDC cross-linker.23 MTX-HSA NPs 
showed suitable cytotoxic effects in vitro but their delivery to 
the tumor site is through passive targeting. Active targeting, 
mediated by specific receptors on the surface of tumor cells, 
could increase the uptake of targeted NPs by tumor cells. To 
increase the antitumor effect of MTX-HSA NPs, we func-
tionalized these NPs by biotin molecules.19 Three types of 
biotin functionalized MTX-HSA NPs with biotin/HSA molar 
ratios of 3.66, 7.01, and 9.41 were prepared. After biotin con-
jugation, the size of MTX-HSA NPs was increased slightly 
in proportion to the amount of attached biotin molecules. 
The zeta potential of these NPs was decreased to −20 mV 
when functionalized with biotin molecules. The decrease in 
zeta potential may be attributed to the decrease of the free 
amino groups on the MTX-HSA NPs after conjugation of 
the biotin molecules to these groups. The results of a previ-
ous study showed that the cytotoxic effects of biotin targeted 
MTX-HSA NPs on T47D and HeLa tumor cells increased 
significantly compared with non-targeted MTX-HSA NPs 
and free MTX in vitro.19 Moreover, decreasing the cellular 
uptake of biotin targeted MTX-HSA NPs in the presence of 
free biotin molecules confirmed the specific biotin receptor-
mediated endocytosis of biotin targeted NPs. Fluorescence 
microscopy images also confirmed the much higher uptake 
of biotin targeted MTX-HSA NPs in T47D and HeLa tumor 
cells compared with non-targeted MTX-HSA NPs.19 In the 
present study, the antitumor efficacy of biotin targeted MTX-
HSA NPs on 4T1 tumor-bearing mice was investigated, and 
the results reinforced the results of in vitro studies. The results 
of in vivo study showed that free MTX alone could not inhibit 
tumor growth sufficiently and there were no significant dif-
ferences between the tumor size of the group treated with 
free MTX and the control group. The inhibitory effect of 
non-targeted MTX-HSA NPs on tumor growth was slightly 
better than that of free MTX in 4T1 tumor-bearing mice. But 
tumor growth in groups treated with biotin targeted MTX-
HSA NPs was significantly slower than in those treated with 
non-targeted MTX-HSA NPs. Tumor volume 21 days after 
treatment in mice treated with biotin 9.41-MTX-HSA NPs, 
biotin 7.02-MTX-HSA NPs, and biotin 3.66-MTX-HSA 
NPs (equivalent to 12.5 mg/kg free MTX) was, respectively, 
1134.11% ± 89%, 994.10% ± 34%, and 899.02% ± 48% less 
than that of those treated with non-targeted MTX-HSA NPs. 
Similar to in vitro results, biotin targeted MTX-HSA NPs 
with more attached biotin molecules on their surfaces had 
more in vivo antitumor effects compared to NPs with less 
biotin molecules. Moreover, biotin targeted MTX-HSA NPs 
prolonged survival time of 4T1 tumor-bearing mice compared 
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with non-targeted MTX-HSA NPs. Prolonged survival time 
of groups treated with biotin targeted MTX-HSA NPs could 
be related to potent inhibitory effects of tumor growth of 
these NPs, as evidenced by antitumor efficacy results. Lower 
body weight loss in groups treated with biotin targeted MTX-
HSA NPs might be related to the better antitumor effects or 
lower toxicity (side effects) of biotin targeted NPs compared 
with non-targeted MTX-HSA NPs and free MTX. MTX has 
various side effects such as weakness, tiredness, and body 
weight loss. MTX may also disturb food uptake and conse-
quently cause body weight loss.37 It is possible that biotin 
targeting decreased the uptake of MTX-HSA NPs in normal 
organs and decreased the side effects of MTX in these organs. 
Consequently, biotin targeting could transport MTX to the 
tumor site with great efficiency and increase its antitumor 
effect sufficiently in tumor-bearing mice.
Conclusion
Biotin targeted human serum albumin–anticancer drug 
conjugated NPs were developed as a suitable targeted drug 
delivery system to enhance therapeutic effects of MTX and 
reduce its side effects. Biotin targeted MTX-HSA NPs could 
accumulate in cells with overexpression of biotin receptors. 
The in vivo anticancer experiment showed that biotin targeted 
MTX-HSA NPs had stronger antitumor activity and lower 
toxic effect than non-targeted MTX-HSA NPs and free MTX 
in a mouse breast tumor model. Therefore, biotin targeted 
MTX-HSA NPs could be used as a potent anticancer drug 
for treatment of tumors.
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Supplementary data
The biotin targeted MTX-HSA NPs were characterized in 
vitro as below:
Methods
Transmission electron microscopy
The morphology of the biotin functionalized MTX-HSA NPs 
was studied by transmission electron microscopy (TEM). 
A drop of the biotin functionalized MTX-HSA NPs in water 
was placed on a graphite surface and was analyzed by TEM 
(Zeiss EM 900, Jena, Germany) at a voltage of 8 kV .
In vitro release of MTX from biotin  
functionalized NPs
The release of free MTX from biotin functionalized MTX-
HSA NPs was evaluated in PBS pH 7.4 and serum. Twenty 
milligrams of biotin 3.6-MTX-HSA NPs, biotin 7.0-MTX-
HSA NPs and biotin 9.4-MTX-HSA NPs were redispersed 
separately in 2 mL of PBS pH 7.4. The solutions were intro-
duced in to a dialysis tube (cellulose membrane, cutoff 12,000 
Da, Merck, Germany). The tubes were placed into capped, 
wide-mouth jars containing 10 mL of PBS pH 7.4 as release 
medium. These jars were placed in a shaker water bath (37°C) 
for 72 hours. The amount of free MTX was determined in 
0.1 mL of release medium every 24 hours using high-per-
formance liquid chromatography (HPLC) on a Teknokroma 
C18, 4.6 × 250 mm column using a mobile phase consisting 
of phosphate buffer pH 7.2:acetonitrile in the volume ratio 
of 88:12 (ﬂow rate of 1.20 mL/min) at 305 nm (UV detector, 
WellChrom, K-2600, Knauer, Germany).
stability of biotin functionalized  
MTX-hsA NPs
To determine the stability of biotin functionalized MTX-HSA 
NPs, these NPs were resuspended in PBS pH 7.4 (25 mg in 
4 mL) and incubated at 4°C for 6 weeks. The size and zeta 
potential of NPs were measured every week. Every week 
100 µL of nanoparticle suspension was removed and diluted 
by deionized water to 1 mL. The diluted suspension of NPs 
were centrifuged using Amicon® Ultra-4 Centrifugal Filter 
Devices (cutoff: 30 kDa) (Millipore, USA). The filtrate 
was evaluated for the amount of free MTX by HPLC on 
a   Teknokroma C18, 4.6 × 250 mm column using a mobile 
phase consisting of phosphate buffer pH 7.2:acetonitrile 
in the volume ratio of 88:12 (ﬂow rate of 1.20 mL/min) 
at 305 nm (UV detector, WellChrom, K-2600, Knauer, 
  Germany). Moreover the amount of free biotin in filtrate was 
analyzed using HABA/Avidin.
100 nm
Figure S1 Transmission electron microscopy image of biotin 7.01-MTX-hsA NPs. 
Abbreviations: MTX-hsA NP, methotrexate–human serum albumin conjugated 
nanoparticle;  biotin  7.01-MTX-hsA  NPs,  biotin  targeted  methotrexate–human 
serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratio.
Fluorescence microscopy
To obtain direct evidence of the internalization of 
biotin functionalized MTX-HSA NPs compared with 
  non-  functionalized MTX-HSA NPs, biotin functionalized 
MTX-HSA NPs and non-functionalized MTX-HSA NPs 
were labeled by FITC. T47D and HeLa cells were seeded 
in 6-well plates (Costar, IL at a density of 300,000 cells 
per well for 24 hours. After 24 hours, T47D and HeLa 
cells were incubated with fresh culture medium containing 
FITC-labeled biotin functionalized MTX-HSA NPs and 
FITC-labeled non-functionalized MTX-HSA NPs at a con-
centration of 1 mg/mL for 4 hours at 37°C. After 4 hours, 
cells were washed 3 times with PBS and the internalization 
of NPs to cells was visualized using ﬂuorescence microscopy 
(Olympus IX 71, Japan).
results
TeM image
TEM image of biotin functionalized MTX-HSA NPs 
  ( Figure S1) reveals their homogeneous size distribution.
In vitro release of MTX from biotin  
functionalized NPs
After 72 hours incubation of biotin functionalized MTX-HSA 
NPs in PBS pH 7.4 only 4.22% ± 0.21%, 5.10% ± 0.34%, 
and 4.56% ± 0.55% of MTX were released from biotin 
3.6-MTX-HSA NPs, biotin 7.0-MTX-HSA NPs, and biotin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1873
Biotin-MTX-hsA conjugates against breast tumors
80
01234
Week
567
100
120
140
160
−40
−20
0
20
40
Z
e
t
a
 
p
o
t
e
n
t
i
a
l
 
(
m
V
)
S
i
z
e
 
(
n
m
)
Figure S2 storage stability of biotin 7.01-MTX-hsA NPs. size and zeta potential of NPs were recorded for 6 weeks.
Abbreviations: NP, nanoparticle; MTX-hsA NP, methotrexate–human serum albumin conjugated nanoparticle; biotin 7.01-MTX-hsA NPs, biotin targeted methotrexate–
human serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratio.
Figure S3 The uptake of FITc-labeled non-targeted MTX-hsA NPs (A) biotin 3.66-MTX-hsA NPs (B), biotin 7.01-MTX-hsA NPs (C), biotin 9.41-MTX-hsA NPs (D) at 
concentration of 1 mg/mL to T47D tumor cells after 4 hours at 37°c. The uptake of FITc-labeled non-targeted MTX-hsA NPs (E), biotin 3.66-MTX-hsA NPs (F), biotin 
7.01-MTX-hsA NPs (G), biotin 9.41-MTX-hsA NPs (h) at concentration of 1 mg/mL to heLa tumor cells after 4 hours at 37°c.
Abbreviations: FITc, ﬂuorescein isothiocyanate; MTX, methotrexate; MTX-HSA NP, methotrexate–human serum albumin conjugated nanoparticle; biotin 3.66-MTX-HSA 
NPs, biotin targeted methotrexate–human serum albumin nanoparticles: 3.66 ± 0.22 biotin/human serum albumin molar ratio; biotin 7.01-MTX-hsA NPs, biotin targeted 
methotrexate–human serum albumin nanoparticles: 7.01 ± 0.14 biotin/human serum albumin molar ratio; biotin 9.41-MTX-hsA NPs, biotin targeted methotrexate–human 
serum albumin nanoparticles: 9.41 ± 0.34 biotin/human serum albumin molar ratio.
9.4-MTX-HSA NPs, respectively. After incubation of 
biotin targeted MTX-HSA NPs in serum, 9.35% ± 0.45%, 
10.46% ± 0.12% and 10.11% ± 0.33% of MTX were released.
stability studies
The release of free MTX and biotin from biotin functional-
ized MTX-HSA NPs was estimated in aqueous buffered 
solution at 4°C. After storage, at least 96.2% of MTX was still 
linked to HSA and only 1.2% of biotin molecules had been 
released. The size and zeta potential of these NPs remained 
unchanged after 6 weeks at 4°C (Figure S2).
Fluorescence microscopy
Internalization of FITC-labeled biotin functionalized MTX-
HSA NPs and FITC-labeled non-functionalized MTX-HSA 
NPs by T47D and HeLa cells was also investigated by International Journal of Nanomedicine
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ﬂuorescence microscopy. After 4 hours incubation of T47D 
cells with the FITC-labeled biotin functionalized MTX-
HSA NPs and FITC labeled non-functionalized MTX-HSA 
NPs at 37°C, T47D cells treated with FITC-labeled biotin 
functionalized MTX-HSA NPs (Figure S3B–D) showed 
significantly more intense ﬂuorescence than T47D cells 
treated with FITC-labeled non-functionalized MTX-HSA 
NPs (Figure S3A). The uptake of FITC-labeled biotin func-
tionalized MTX-HSA NPs in HeLa cells (Figure S3F–H) was 
also greater than that of FITC-labeled non-functionalized 
MTX-HSA NPs (Figure S3E).